+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Crohn's Disease (Regional Enteritis) (Gastrointestinal) - Drugs In Development, 2021

  • PDF Icon

    Report

  • 839 Pages
  • July 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5402570
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease - Drugs In Development, 2021, provides an overview of the Crohn's Disease (Gastrointestinal) pipeline landscape.

Crohn’s disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of digestive tract, which can lead to abdominal pain, severe diarrhea and even malnutrition. Inflammation caused by Crohn’s disease can involve different areas of the digestive tract in different people. Signs and symptoms may include diarrhea, abdominal pain and cramping, blood in stool, ulcers, reduced appetite and weight loss. Risk factor include age, family history, smoking and use of Non-steroidal anti-inflammatory medications.

Report Highlights


The publisher's Pharmaceutical and Healthcare latest pipeline guide Crohn's Disease - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Crohn's Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Crohn's Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 17, 41, 32, 3, 68, 31 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 1 molecules, respectively.

Crohn's Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Crohn's Disease (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Crohn's Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Crohn's Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Crohn's Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Crohn's Disease (Gastrointestinal)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Crohn's Disease (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Crohn's Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction
Crohn's Disease (Regional Enteritis) - Overview
  • Crohn's Disease (Regional Enteritis) - Therapeutics Development
Crohn's Disease (Regional Enteritis) - Therapeutics AssessmentCrohn's Disease (Regional Enteritis) - Companies Involved in Therapeutics DevelopmentCrohn's Disease (Regional Enteritis) - Drug ProfilesCrohn's Disease (Regional Enteritis) - Dormant ProjectsCrohn's Disease (Regional Enteritis) - Discontinued ProductsCrohn's Disease (Regional Enteritis) - Product Development MilestonesAppendix
List of Tables
  • Number of Products under Development for Crohn's Disease (Regional Enteritis), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by 4D Pharma Plc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by 9 Meters Biopharma Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by AbbVie Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Abivax SA, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Aclaris Therapeutics Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Active Biotech AB, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Affilogic SAS, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by AIBIOS Co Ltd, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Alfasigma SpA, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Algernon Pharmaceuticals Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Alpha Cancer Technologies Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Alvotech ehf, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Amide Technologies Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Anterogen Co Ltd, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Arena Pharmaceuticals Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Artelo Biosciences Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Artizan Biosciences Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Asdera LLC, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Assembly Biosciences Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by AstraZeneca Plc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Atlantic Healthcare Plc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Avexegen Therapeutics Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Avobis Bio LLC, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Avotres Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Axim Biotechnologies Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Bio-Thera Solutions Ltd, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by BioLingus AG, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by BioXpress Therapeutics SA, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Boehringer Ingelheim International GmbH, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Bristol-Myers Squibb Co, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Cellivery Therapeutics Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Celltrion Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Cellvation Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Celularity Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Cerecor Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by ChemoCentryx Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by ChunLab Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Cloud Pharmaceuticals Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Curacle Co Ltd, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by CVasThera, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Cytocom Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Cytodyn Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Dadang & BIO Co Ltd, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Daiichi Sankyo Co Ltd, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by DBV Technologies SA, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Defensin Therapeutics ApS, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Temisis Therapeutics, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Tetherex Pharmaceuticals Corp, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by The Cell Factory BVBA, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Theravance Biopharma Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Thetis Pharmaceuticals LLC, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Tiziana Life Sciences Plc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by TRACT Therapeutics Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Trio Medicines Ltd, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by UCB SA, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Ventyx Biosciences Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by VHsquared Ltd, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by VITAbolus Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Winston Pharmaceuticals Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by XBiotech Inc, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Xbrane Biopharma AB, 2021
  • Crohn's Disease (Regional Enteritis) - Pipeline by Yom Chai, 2021
  • Crohn's Disease (Regional Enteritis) - Dormant Projects, 2021
  • Crohn's Disease (Regional Enteritis) - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Crohn's Disease (Regional Enteritis), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 4D Pharma Plc
  • 9 Meters Biopharma Inc
  • AbbVie Inc
  • Abivax SA
  • Aclaris Therapeutics Inc
  • Active Biotech AB
  • Affilogic SAS
  • AIBIOS Co Ltd
  • Alfasigma SpA
  • Algernon Pharmaceuticals Inc
  • Alpha Cancer Technologies Inc
  • Alvotech ehf
  • Amide Technologies Inc
  • Anterogen Co Ltd
  • Arena Pharmaceuticals Inc
  • Artelo Biosciences Inc
  • Artizan Biosciences Inc
  • Asdera LLC
  • Assembly Biosciences Inc
  • AstraZeneca Plc
  • Atlantic Healthcare Plc
  • Avexegen Therapeutics Inc
  • Avobis Bio LLC
  • Avotres Inc
  • Axim Biotechnologies Inc
  • Bio-Thera Solutions Ltd
  • BioLingus AG
  • BioXpress Therapeutics SA
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • Cellivery Therapeutics Inc
  • Celltrion Inc
  • Cellvation Inc
  • Celularity Inc
  • Cerecor Inc
  • ChemoCentryx Inc
  • Chong Kun Dang Pharmaceutical Corp
  • ChunLab Inc
  • Cloud Pharmaceuticals Inc
  • Curacle Co Ltd
  • CVasThera
  • Cytocom Inc
  • Cytodyn Inc
  • Dadang & BIO Co Ltd
  • Daiichi Sankyo Co Ltd
  • DBV Technologies SA
  • Defensin Therapeutics ApS
  • Deka Biosciences Inc
  • Denali Therapeutics Inc
  • DM Bio Ltd
  • DNX Biopharmaceuticals Inc
  • EA Pharma Co Ltd
  • Eden Biologics Inc
  • Educell doo
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Enterome Bioscience SA
  • Enzo Biochem Inc
  • Evergreen Therapeutics Inc
  • Exeliom Biosciences SAS
  • Ferring International Center SA
  • Finch Therapeutics Group Inc
  • FYB 202 GmbH & Co KG
  • Galactica Biotech Ltd
  • Galapagos NV
  • Genentech USA Inc
  • Genor BioPharma Co Ltd
  • Giiant Pharma Inc
  • GlaxoSmithKline Plc
  • Gossamer Bio Inc
  • Gusto Global LLC
  • HAV Vaccines Ltd
  • Hoth Therapeutics Inc
  • Iltoo Pharma
  • Immunic Inc
  • Inception Sciences Inc
  • InflammatoRx inc
  • Innovation Pharmaceuticals Inc
  • Innovative Pharmacological Research (IPHAR) Co Ltd
  • Innovent Biologics Inc
  • Innovimmune Biotherapeutics Inc
  • InSight Biopharmaceuticals Ltd
  • Inspyr Therapeutics Inc
  • Intract Pharma Ltd
  • Jiangsu Carephar Pharmaceutical Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • JiangSu Qyuns Therapeutics Co Ltd
  • Johnson & Johnson
  • Jyant Technologies Inc
  • Koutif Therapeutics LLC
  • Kyorin Pharmaceutical Co Ltd
  • Landos Biopharma Inc
  • Machavert Pharmaceuticals LLC
  • MAKScientific LLC
  • Mesoblast Ltd
  • Metacrine Inc
  • Metagen Therapeutics Inc
  • MetiMedi Pharmaceuticals Co Ltd
  • MGC Pharmaceuticals Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Morphic Therapeutic Inc
  • MRM Health NV
  • Mycenax Biotech Inc
  • NeuClone Pty Ltd
  • Nichi-Iko Pharmaceutical Co Ltd
  • Oncodesign SA
  • Orchard Therapeutics Plc
  • Origo Biopharma SL
  • PanTheryx Inc
  • Par'Immune SAS
  • Paradigm Biopharmaceuticals Ltd
  • PeLeMed Co Ltd
  • Pfizer Inc
  • Pharmapraxis
  • Polpharma Biologics SA
  • Praeventix LLC
  • Prometheus Biosciences Inc
  • Protagonist Therapeutics Inc
  • Puretech Health Plc
  • Qu Biologics Inc
  • Re-Pharm Ltd
  • Rebiotix Inc
  • RedHill Biopharma Ltd
  • Redx Pharma Plc
  • Regentys Corp
  • Reistone Biopharma Co Ltd
  • Reponex Pharmaceuticals AS
  • Saje Pharma LLC
  • Samsung Bioepis Co Ltd
  • Saniona AB
  • Semorex Technologies Ltd
  • Seres Therapeutics Inc
  • Servatus Ltd
  • Siam Bioscience Co Ltd
  • SLA Pharma AG
  • Soligenix Inc
  • Steel Therapeutics Inc
  • Stempeutics Research Pvt Ltd
  • STERO Biotechs Ltd
  • Sublimity Therapeutics HoldCo Ltd
  • Suono Bio Inc
  • Surrozen Inc
  • Suzhou Connect Biopharmaceuticals Ltd
  • Suzhou Pharmavan Cancer Research Center Co Ltd
  • Synedgen Inc
  • Synlogic Inc
  • TaiwanJ Pharmaceuticals Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Temisis Therapeutics
  • Tetherex Pharmaceuticals Corp
  • The Cell Factory BVBA
  • Theravance Biopharma Inc
  • Thetis Pharmaceuticals LLC
  • Tiziana Life Sciences Plc
  • TRACT Therapeutics Inc
  • Trio Medicines Ltd
  • UCB SA
  • Ventyx Biosciences Inc
  • VHsquared Ltd
  • VITAbolus Inc
  • Winston Pharmaceuticals Inc
  • XBiotech Inc
  • Xbrane Biopharma AB
  • Yom Chai